Novel Treatments for Ocular Surface Diseases
Novel Treatments for Ocular Surface Diseases
批准号:
10795227
负责人:
Vinay Aakalu
金额:
$38.81万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-04-01 至 2025-03-31
关键词:
AddressAdvanced DevelopmentAffectAnimalsAnti-Infective AgentsAnti-Inflammatory AgentsAutophagocytosisBenzalkonium ChlorideBindingBinding ProteinsBiological AssayCell Culture TechniquesClinicalCopperCorneaCustomDataDesiccationDevelopmentDiseaseDisease modelDrug FormulationsDry Eye SyndromesEndosomesEnsureEnvironmentEnzymesEpitheliumExposure toFamilyFilmFunctional disorderFutureG-Protein-Coupled ReceptorsGlaucomaHistidineHomeostasisHumanHumidityIL8 geneIn VitroInflammationInflammation MediatorsInflammatoryInhibition of Matrix Metalloproteinases PathwayInterleukin-6Lacrimal gland structureLigandsMammalian CellMatrix MetalloproteinasesMeasuresMediatingMediatorMetalsMethodsModelingMucositisNickelOralOsmolar ConcentrationOutcomePatientsPeptide HydrolasesPeptidesPharmaceutical PreparationsPhysiologicalProductionPropertyProteinsProtocols documentationPublishingQuality of lifeResearchSalivaStressSystemTestingTherapeuticTherapeutic EffectToxic effectToxicant exposureVisionantimicrobialantimicrobial peptideclinically relevantcorneal epitheliumcytokinedesignexperienceexperimental studyhistatin 1histidine-rich proteinsimprovedin vivoin vivo Modelinnovationlacrimalmigrationmouse modelnovelnovel therapeuticsocular surfaceocular surface diseaseophthalmic drugpalliativereceptorscreeningsynthetic peptidetranslational modelvisual dysfunctionwound healing
中文摘要
项目描述/文摘
英文摘要
PROJECT DESCRIPTION/ABSTRACT
Dry eye disease (DED) and other ocular surface diseases (OSD) are common conditions that can reduce visual
function and quality of life. Commonly used ophthalmic preservatives can cause a toxic epitheliopathy that
results in OSD. The treatment of these diseases is primarily through the use of palliative measures. Great
opportunity exists to improve the quality of life of many patients by developing novel treatments. DED and OSD
are associated with significant dysfunction of corneal epithelia and inflammatory changes on the ocular surface.
Many of these changes are induced by hyperosmolarity, desiccation and inflammatory insults. Histatin is a family
of peptides found primarily in saliva and is known to have significant wound healing and anti-infective properties.
Little data exist on the mechanisms of action of histatin peptides, though some effects are thought to be
mediated through as yet unknown receptors. We have found that these peptides can reduce inflammatory
changes associated with exposures of toxic preservatives to the ocular surface and in experimental conditions
that mimic DED. We have also found a potential novel ligand-receptor interaction for histatin peptides. Our long
term objective is to develop a new class of DED and OSD therapeutics which are non-toxic and anti-
inflammatory. Our central hypothesis is that histatin peptides can ameliorate the inflammatory effects of toxic
and inflammatory insults to corneal epithelia in vitro and in vivo. We will utilize well vetted models of toxic
epitheliopathy, hyperosmolarity and desiccation in order to show the efficacy of histatin peptides in treating
OSDs. We will also undertake studies to find receptors for histatin peptide. The proposed research is innovative
as it is the first study to investigate the use of histatin peptides in the treatment of DED and OSD. These studies
are significant because they will advance the development of new therapeutics through the use of rigorous and
well defined methods in clinically relevant translational models of disease and validate a novel receptor-ligand
relationship.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/acs.jmedchem.3c00959
发表时间:
2023-08-24
期刊:
JOURNAL OF MEDICINAL CHEMISTRY
影响因子:
7.3
作者:
[Dichiara, Maria, Ambrosio, Francesca Alessandra, Lee, Sang Min, Ruiz-Cantero, M. Carmen, Lombino, Jessica, Coricello, Adriana, Costa, Giosue, Shah, Dhara, Costanzo, Giuliana, Pasquinucci, Lorella, Son, Kyung No, Cosentino, Giuseppe, Gonzalez-Cano, Rafael, Marrazzo, Agostino, Aakalu, Vinay Kumar, Cobos, Enrique J., Alcaro, Stefano, Amata, Emanuele]
通讯作者:
Amata, Emanuele
Novel Therapeutic Approaches for NPC Disease
-
批准号:10650430
-
项目类别:
-
资助金额:$57.56万
-
财政年份:2022
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Ocular Surface Diseases
-
批准号:10376340
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Ocular Surface Diseases
-
批准号:10225306
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Ocular Surface Diseases
-
批准号:9902473
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2019
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases
-
批准号:9562360
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases
-
批准号:10292904
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases
-
批准号:10046282
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Vinay Aakalu
-
依托单位:
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases
-
批准号:10516064
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Vinay Aakalu
-
依托单位:
Study of Accessory Lacrimal Gland and Precursor Cell Biology
-
批准号:9044784
-
项目类别:
-
资助金额:$23.64万
-
财政年份:2014
-
负责人:Vinay Aakalu
-
依托单位:
Study of Accessory Lacrimal Gland and Precursor Cell Biology
-
批准号:8679183
-
项目类别:
-
资助金额:$23.64万
-
财政年份:2014
-
负责人:Vinay Aakalu
-
依托单位:
Cellular and Molecular Biology Core
-
批准号:10273645
-
项目类别:
-
资助金额:$18.37万
-
财政年份:1997
-
负责人:Vinay Aakalu
-
依托单位:
Cellular and Molecular Biology Core
-
批准号:10704037
-
项目类别:
-
资助金额:$18.37万
-
财政年份:1997
-
负责人:Vinay Aakalu
-
依托单位:
Cellular and Molecular Biology Core
-
批准号:10475738
-
项目类别:
-
资助金额:$18.37万
-
财政年份:1997
-
负责人:Vinay Aakalu
-
依托单位:
Cellular and Molecular Biology Core
-
批准号:10020553
-
项目类别:
-
资助金额:$17.54万
-
财政年份:1997
-
负责人:Vinay Aakalu
-
依托单位:
海外基金